QBF ups Glycoz investment
Friday, 14 January, 2005
Queensland BioCapital Funds has invested a further $1.9 million in antibiotic-developer Glycoz, bringing its total stake in the company to $2.4 million
Glycoz is developing carbohydrate-based antibiotics based on research by Professors Mark von Itzstein and Ross Coppel.
The funding, in conjunction with a $1.8 million R&D Start Grant, will be used to take the company's lead compound through pre-clinical drug development.
QBF -- a $100 million closed end venture capital fund -- is a wholly-owned subsidiary of the Queensland Investment Corporation. It recently increased its holding in Brisbane unlisted biotech Xenome, taking up shares sold by Biotech Capital (ASX:BTC) and Cytopia (ASX:CTY).
In December, QIC's Neill Colledge replaced Kathryn Radford as CEO of QBF.
Link between oestrogen and heart health found in women
Scientists found that oestrogen helps increase the ANXA1 protein, and when ANXA1 is missing, the...
Frequent nightmares accelerate aging, increase risk of death
Nghtmares independently predict faster biological aging and earlier mortality — even after...
Cardiac organoids bring hope for treating heart disease
Australian scientists have developed lab-grown, three-dimensional heart tissues known as cardiac...
